Key regions: France, Europe, United Kingdom, Brazil, India
The Oncology Drugs market in Bhutan is experiencing significant growth in recent years, driven by several factors.
Customer preferences: Bhutan has a growing demand for Oncology Drugs due to the increasing prevalence of cancer in the country. According to the Bhutan Cancer Society, cancer is the third leading cause of death in the country, with breast and cervical cancers being the most common among women. As a result, there is a high demand for Oncology Drugs that can treat these types of cancer.
Trends in the market: The Oncology Drugs market in Bhutan is primarily driven by the increasing availability of generic drugs. Generic drugs are less expensive than branded drugs, making them more accessible to patients who may not have the financial means to purchase expensive branded drugs. Additionally, the government of Bhutan has implemented policies to increase the availability of generic drugs, which has further boosted the growth of the Oncology Drugs market.
Local special circumstances: Bhutan is a small country with a population of just over 750,000 people. The country has limited healthcare infrastructure and resources, which has made it difficult for patients to access Oncology Drugs. However, the government of Bhutan has taken steps to address this issue by increasing funding for healthcare and implementing policies to improve access to healthcare services.
Underlying macroeconomic factors: Bhutan has a growing economy, with a GDP growth rate of 5.7% in 2019. The country's healthcare sector is also growing, with the government investing more resources into healthcare infrastructure and services. This has created a favorable environment for the growth of the Oncology Drugs market in Bhutan.In conclusion, the Oncology Drugs market in Bhutan is experiencing significant growth due to the increasing demand for Oncology Drugs, the availability of generic drugs, and the government's efforts to improve access to healthcare services. Despite the challenges posed by limited healthcare infrastructure and resources, the market is expected to continue to grow in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
